Pharma Journalist 9158 posts 0 comments

Octant has received Orphan Drug Designation from the US Food and Drug Administration (FDA) for OCT-980, an investigational oral drug being developed to treat retinitis pigmentosa, a…
Read More...

Regeneron Pharmaceuticals has extended its agreement with the US government to provide additional supplies of Inmazeb, an antibody-based treatment for Ebola disease. The expanded…
Read More...

Pfizer has received US Food and Drug Administration (FDA) approval to expand the use of Talzenna (talazoparib) in combination with Xtandi (enzalutamide) for men with a specific type of…
Read More...

Astellas Pharma and Australian biotechnology company Audax Biosciences have entered into an exclusive option and license agreement for DAX-044, an investigational cancer immunotherapy…
Read More...

Arrowhead Pharmaceuticals has announced that adults living with familial chylomicronaemia syndrome (FCS) in England and Wales will have access to REDEMPLO (plozasiran), a new treatment…
Read More...

Regeneron Pharmaceuticals has reported new long-term data showing that Libtayo (cemiplimab) may help reduce the risk of death in patients with high-risk cutaneous squamous cell…
Read More...

Astellas Pharma has announced that China’s National Medical Products Administration (NMPA) has accepted a new drug application for Veoza (fezolinetant) 45 mg, a non-hormonal treatment…
Read More...

Lunit and Summit Therapeutics have entered into a research agreement to use artificial intelligence (AI) to study the tumor microenvironment and support the development of new cancer…
Read More...

ScionxBio has entered into a worldwide research collaboration and licensing agreement with Sanofi to develop longer-lasting RNA-based medicines. The partnership will use ScionxBio’s…
Read More...

AI Proteins has signed a research collaboration and licensing agreement with Astellas Pharma to discover and develop new miniprotein-based medicines using artificial intelligence (AI).…
Read More...